The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
The company’s EBITDA margin remained resilient above 20%
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
This achievement validates global demand and catapults Wanbury into high-growth acceleration
Subscribe To Our Newsletter & Stay Updated
